Celgene Files For Approval Of Revlimid In Japan – On July 7, Celgene announced that it filed a New Drug Application (NDA) for Revlimid (lenalidomide) with the Japanese Ministry of Health, Labour, and Welfare.  The application seeks approval for the use of Revlimid in combination with dexamethasone (Decadron) for myeloma patients who have received at least one previous therapy. The filing is based on the results of two large Phase 3 trials from 2007 that demonstrated the efficacy of this treatment regimen. Phase 1 trials with Japanese patients show similar results and also support the NDA. Revlimid is approved in almost 50 countries for the treatment of multiple myeloma. For more information, please visit the Celgene press release.

99th Annual Wamp Swim-a-Thon – On July 18, the International Myeloma Foundation (IMF) is sponsoring a swim-a-thon to benefit the Jeffrey R. Stafford fund at the IMF, used to benefit patients suffering from multiple myeloma. Currently, participants have raised around $100,000 and produced three research grants to aid in research about multiple myeloma.  The fund is in honor of Jeffrey Stafford, who was diagnosed with myeloma in 2001. For more information, please visit the IMF Web site.

For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.